Clinical Trial
doi: 10.1111/j.1749-6632.2001.tb03721.x.
The role for interleukin-12 therapy of cutaneous T cell lymphoma
Affiliations
- PMID: 11594571
- DOI: 10.1111/j.1749-6632.2001.tb03721.x
Item in Clipboard
Clinical Trial
The role for interleukin-12 therapy of cutaneous T cell lymphoma
Ann N Y Acad Sci.
2001 Sep.
Abstract
Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.
Similar articles
-
Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses.Blood. 1999 Aug 1;94(3):902-8. Blood. 1999. PMID: 10419880 Clinical Trial.
-
Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2.Hematol Oncol Clin North Am. 2003 Dec;17(6):1435-48, ix. doi: 10.1016/s0889-8588(03)00109-6. Hematol Oncol Clin North Am. 2003. PMID: 14710894 Review.
-
Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma.Adv Dermatol. 2002;18:29-43. Adv Dermatol. 2002. PMID: 12528401 Review.
-
Crosstalk between tumor T lymphocytes and reactive T lymphocytes in cutaneous T cell lymphomas.Ann N Y Acad Sci. 2001 Sep;941:31-8. doi: 10.1111/j.1749-6632.2001.tb03708.x. Ann N Y Acad Sci. 2001. PMID: 11594580
-
Targeting Tumor-Infiltrating B Cells in Cutaneous T-Cell Lymphoma.J Clin Oncol. 2016 Apr 20;34(12):e110-6. doi: 10.1200/JCO.2013.50.9471. Epub 2014 Oct 27. J Clin Oncol. 2016. PMID: 25348001 No abstract available.
Cited by
-
Harnessing the immune system in the treatment of cutaneous T cell lymphomas.Front Oncol. 2023 Jan 12;12:1071171. doi: 10.3389/fonc.2022.1071171. eCollection 2022. Front Oncol. 2023. PMID: 36713518 Free PMC article.
-
Proteomic Profiling Change and Its Implies in the Early Mycosis Fungoides (MF) Using Isobaric Tags for Relative and Absolute Quantification (iTRAQ).Biomed Res Int. 2020 Nov 23;2020:9237381. doi: 10.1155/2020/9237381. eCollection 2020. Biomed Res Int. 2020. PMID: 33299887 Free PMC article.
-
Abrogation of TNFα production during cancer immunotherapy is crucial for suppressing side effects due to the systemic expression of IL-12.PLoS One. 2014 Feb 28;9(2):e90116. doi: 10.1371/journal.pone.0090116. eCollection 2014. PLoS One. 2014. PMID: 24587231 Free PMC article.
-
Gene expression analysis in Interleukin-12-induced suppression of mouse mammary carcinoma.Int J Cancer. 2004 Jul 1;110(4):570-8. doi: 10.1002/ijc.20145. Int J Cancer. 2004. PMID: 15122590 Free PMC article.
-
Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy.Blood. 2006 Apr 15;107(8):3189-96. doi: 10.1182/blood-2005-07-2813. Epub 2006 Jan 10. Blood. 2006. PMID: 16403914 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
